The retrospective study presented at ESMO 2024 involved about 2,400 patients with stage 3 or 4 non-small cell lung cancer.

Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...

Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene shareholders by ...

Italian Prime Minister Giorgia Meloni met the head of the U.S. fund BlackRock Inc , Larry Fink, in Rome on Monday to discuss ...

Prime Medicine will partner with Bristol Myers Squibb (BMS) to develop and commercialize an unspecified number of reagents for ex vivo T-cell therapies through a collaboration that could generate more ...

Prime Medicine (PRME) shares rallied 15% Monday after the company announced a collaboration with Bristol Myers (BMY), which ...

The firm is focusing on hematology, immunology, and oncology, liver, and lung conditions, while seeking partnerships beyond these core areas.

The high-profile biotech is zeroing in on programs that serve as proof points for its technology, while seeking partners for other assets.

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

MM+M’s 2024 Healthcare Marketers Trend Report reveals that AI and tech are top of mind for healthcare marketers. In this recent #TrendTalks session titled “The Ideal Customer Experience Across the ...

After putting on a strong performance in preventing disease progression in the earlier treatment of multiple myeloma, Johnson ...